XAIR:NASDAQ, Beyond Air, Inc.
XAIR stock overview
Beyond Air, Inc. (XAIR:NASDAQ) closed at $2.29 on November 9, 2026,
up 5.79% on the day.
The stock trades 95.7% below its 52-week high of $53.20
and 11.5% above its 52-week low of $2.05.
Over the past year, it lost 93.4%.
Beyond Air, Inc. is part of the Health Care sector (Medical/Dental Instruments).
Key figures
- Price
- $2.29
- Day change
- +5.79%
- Volume
- 11,826
- Average volume
- 215,893
- Market cap
- 3M+
- 52-week range
- $2.05 – $53.20
- 50-day average
- $2.71
- 200-day average
- $9.48
Price action over the past year
In 252 trading sessions since November 7, 2025, XAIR closed higher on 93 days (37%).
Its best day was January 13, 2026 (+150.00%) and its worst was July 14, 2026 (-22.96%).
The stock moved 10% or more in a single session 29 times.
It opened at least 5% above the previous day's high 4 times.
Recent signals
XAIR news
-
Oct 29, 2026:
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026
-
Oct 8, 2026:
Beyond Air Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
-
Oct 8, 2026:
Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
-
Sep 2, 2026:
Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
-
Aug 31, 2026:
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
-
Aug 31, 2026:
Beyond Air Receives FDA Breakthrough Device Designation for LungFit GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
-
Aug 25, 2026:
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
-
Aug 14, 2026:
Beyond Air (XAIR) Q1 2027 Earnings Call Transcript
About Beyond Air, Inc.
Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company which develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Similar stocks
Find more stocks like XAIR with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.